

Kurt Ballmer-Hofer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4215767/publications.pdf>

Version: 2024-02-01

93
papers

6,362
citations

70961

41
h-index

66788

78
g-index

95
all docs

95
docs citations

95
times ranked

8545
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. <i>Nature Medicine</i> , 2003, 9, 936-943.	15.2	699
2	Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. <i>British Journal of Cancer</i> , 2006, 95, 272-281.	2.9	564
3	Antennapedia and HIV Transactivator of Transcription (TAT) α -Protein Transduction Domains Promote Endocytosis of High Molecular Weight Cargo upon Binding to Cell Surface Glycosaminoglycans. <i>Journal of Biological Chemistry</i> , 2003, 278, 35109-35114.	1.6	378
4	The role of VEGF receptors in angiogenesis; complex partnerships. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 601-615.	2.4	325
5	Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. <i>Blood</i> , 2011, 118, 816-826.	0.6	178
6	Structure and function of VEGF receptors. <i>IUBMB Life</i> , 2009, 61, 915-922.	1.5	175
7	A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 2067-2077.	2.4	168
8	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. <i>Blood</i> , 2010, 116, 3677-3680.	0.6	163
9	Structural determinants of growth factor binding and specificity by VEGF receptor 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2425-2430.	3.3	160
10	Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. <i>Blood</i> , 2008, 112, 3638-3649.	0.6	143
11	A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. <i>Blood</i> , 2009, 114, 5236-5244.	0.6	140
12	Structure of a VEGF-VEGF receptor complex determined by electron microscopy. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 249-250.	3.6	137
13	Constitutive activation of protein kinase B and phosphorylation of p47 phox by a membrane-targeted phosphoinositide 3-kinase. <i>Current Biology</i> , 1996, 6, 1271-1278.	1.8	132
14	VEGF transiently disrupts gap junctional communication in endothelial cells. <i>Journal of Cell Science</i> , 2001, 114, 1229-1235.	1.2	132
15	Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010, 1804, 567-580.	1.1	128
16	Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1889-1904.	3.0	112
17	VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. <i>Nature Communications</i> , 2016, 7, 11017.	5.8	111
18	Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. <i>Blood</i> , 2012, 119, 1781-1788.	0.6	108

#	ARTICLE	IF	CITATIONS
19	VEGF transiently disrupts gap junctional communication in endothelial cells. <i>Journal of Cell Science</i> , 2001, 114, 1229-35.	1.2	105
20	Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 1785-94.	2.4	104
21	VEGFR-2 conformational switch in response to ligand binding. <i>ELife</i> , 2016, 5, e13876.	2.8	94
22	Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12960-12965.	3.3	84
23	Highly efficient baculovirus-mediated multigene delivery in primary cells. <i>Nature Communications</i> , 2016, 7, 11529.	5.8	83
24	Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A. <i>Structure</i> , 2017, 25, 341-352.	1.6	77
25	Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. <i>Blood</i> , 2011, 117, 1507-1515.	0.6	76
26	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5257-5267.	3.2	75
27	Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. <i>European Journal of Cancer</i> , 2008, 44, 1883-1894.	1.3	73
28	Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. <i>British Journal of Cancer</i> , 2002, 87, 106-112.	2.9	70
29	Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. <i>Neurobiology of Disease</i> , 2014, 71, 245-259.	2.1	65
30	Vascular Endothelial Growth Factor (VEGF) and Its Receptors in Tumor-Bearing Dogs. <i>Biological Chemistry</i> , 1999, 380, 1449-54.	1.2	60
31	Reconstitution of Two Recombinant LSm Protein Complexes Reveals Aspects of Their Architecture, Assembly, and Function. <i>Journal of Biological Chemistry</i> , 2005, 280, 16066-16075.	1.6	58
32	A plasmid-based multigene expression system for mammalian cells. <i>Nature Communications</i> , 2010, 1, 120.	5.8	55
33	Association of p60c-src with polyoma virus middle-T antigen abrogating mitosis-specific activation. <i>Nature</i> , 1991, 350, 431-433.	13.7	53
34	Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase. <i>FEBS Journal</i> , 1993, 214, 281-286.	0.2	50
35	Activation and Nuclear Translocation of Mitogen-activated Protein Kinases by Polyomavirus Middle-T or Serum Depend on Phosphatidylinositol 3-Kinase. <i>Journal of Biological Chemistry</i> , 1995, 270, 29286-29292.	1.6	49
36	Orf virus VEGF α NZ2 promotes paracellular NRP α 1/VEGFR α 2 coreceptor assembly via the peptide RPPR. <i>FASEB Journal</i> , 2008, 22, 3078-3086.	0.2	49

#	ARTICLE	IF	CITATIONS
37	The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 1572-1580.	1.2	49
38	Transmembrane domain-mediated orientation of receptor monomers in active VEGFR dimers. <i>FASEB Journal</i> , 2010, 24, 32-38.	0.2	48
39	Structural and Functional Characterization of Alternative Transmembrane Domain Conformations in VEGF Receptor 2 Activation. <i>Structure</i> , 2014, 22, 1077-1089.	1.6	43
40	Phage-Derived Fully Human Monoclonal Antibody Fragments to Human Vascular Endothelial Growth Factor-C Block Its Interaction with VEGF Receptor-2 and 3. <i>PLoS ONE</i> , 2010, 5, e11941.	1.1	43
41	Stimulation of c-Src by prolactin is independent of Jak2. <i>Biochemical Journal</i> , 2000, 345, 17.	1.7	41
42	Targeting Extracellular Domains D4 and D7 of Vascular Endothelial Growth Factor Receptor 2 Reveals Allosteric Receptor Regulatory Sites. <i>Molecular and Cellular Biology</i> , 2012, 32, 3802-3813.	1.1	38
43	Polyomavirus middle-T antigen associates with the kinase domain of Src-related tyrosine kinases. <i>Journal of Virology</i> , 1996, 70, 1323-1330.	1.5	37
44	A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. <i>Oncogene</i> , 1997, 14, 1235-1241.	2.6	36
45	Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. <i>Cancer Letters</i> , 2006, 235, 298-308.	3.2	36
46	Structural analysis of vascular endothelial growth factor receptor/ligand complexes by small angle X-ray solution scattering. <i>FASEB Journal</i> , 2011, 25, 2980-2986.	0.2	36
47	Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism. <i>Oncogene</i> , 1998, 16, 903-907.	2.6	35
48	Production of Functionalized Single-Chain Fv Antibody Fragments Binding to the ED-B Domain of the B-isoform of Fibronectin in <i>Pichia pastoris</i> . <i>Protein Expression and Purification</i> , 2001, 21, 156-164.	0.6	34
49	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. <i>Oncotarget</i> , 2016, 7, 35353-35368.	0.8	34
50	Acute suppression of albumin synthesis in systemic inflammatory disease: an individually graded response of rat hepatocytes. <i>Journal of Histochemistry and Cytochemistry</i> , 1992, 40, 201-206.	1.3	32
51	VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 49-67.	2.0	31
52	Crystal Structure of the Orf Virus NZ2 Variant of Vascular Endothelial Growth Factor-E. <i>Journal of Biological Chemistry</i> , 2006, 281, 19578-19587.	1.6	30
53	A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through $\alpha_5\beta_1$ integrin. <i>Blood</i> , 2008, 111, 3479-3488.	0.6	30
54	Differential expression of tenascin splicing variants in the chick gizzard and in cell cultures. <i>Cell Differentiation and Development</i> , 1990, 32, 417-423.	0.4	29

#	ARTICLE	IF	CITATIONS
55	The CMT4B disease-causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 307-315.	1.6	28
56	Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors. <i>Veterinary Radiology and Ultrasound</i> , 2004, 45, 247-254.	0.4	26
57	Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain. <i>Journal of Physiology</i> , 2018, 596, 3675-3693.	1.3	26
58	Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. <i>Biochemical Journal</i> , 2001, 353, 569.	1.7	25
59	Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. <i>Biochemical Journal</i> , 2001, 353, 569-578.	1.7	25
60	DNA Tumor Viruses and Src Family Tyrosine Kinases, an Intimate Relationship. <i>Virology</i> , 1997, 227, 271-280.	1.1	21
61	Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling. <i>Angiogenesis</i> , 2018, 21, 533-543.	3.7	21
62	Isolation of in situ crosslinked ligand-receptor complexes using an anticrosslinker specific antibody. <i>Analytical Biochemistry</i> , 1982, 126, 246-250.	1.1	19
63	Functional interaction between the SH2 domain of Fyn and tyrosine 324 of hamster polyomavirus middle-T antigen. <i>Journal of Virology</i> , 1997, 71, 199-206.	1.5	18
64	Mitosis-specific phosphorylation of polyomavirus middle-sized tumor antigen and its role during cell transformation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8113-8117.	3.3	17
65	Herpesvirus saimiri protein StpB associates with cellular Src. <i>Journal of General Virology</i> , 2001, 82, 339-344.	1.3	15
66	Phosphorylation of polyoma middle T antigen and cellular proteins in purified plasma membranes of polyoma virus-infected cells.. <i>EMBO Journal</i> , 1985, 4, 2321-2327.	3.5	14
67	Polyomavirus middle-T antigen lacking a membrane anchor sequence accumulates in the nucleus. <i>Journal of General Virology</i> , 1996, 77, 17-26.	1.3	14
68	Signalling by Src Family Kinases: Lessons Learnt from DNA Tumour Viruses. <i>Cellular Signalling</i> , 1997, 9, 385-393.	1.7	14
69	Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation. <i>FASEB Journal</i> , 2014, 28, 4914-4923.	0.2	14
70	Multimerization of polyomavirus middle-T antigen. <i>Journal of Virology</i> , 1997, 71, 6990-6995.	1.5	13
71	Myristylation and amino-terminal phosphorylation are required for activation of pp60c-src during mitosis. <i>Oncogene</i> , 1993, 8, 575-81.	2.6	13
72	Targeting human cancer cells with VEGF receptor-2-directed liposomes. <i>Oncology Reports</i> , 2005, 13, 319-24.	1.2	13

#	ARTICLE	IF	CITATIONS
73	Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications. International Journal of Molecular Sciences, 2018, 19, 3750.	1.8	12
74	High-level secretion of recombinant full-length streptavidin in <i>Pichia pastoris</i> and its application to enantioselective catalysis. Protein Expression and Purification, 2014, 93, 54-62.	0.6	11
75	Stimulation of pp60c-src kinase activity in FDC-P1 cells by polyoma middle-T antigen and hematopoietic growth factors. Oncogene, 1989, 4, 1433-9.	2.6	11
76	Expression of influenza hemagglutinin-polyoma T-antigen fusion proteins in a rat embryo fibroblast cell line. Virus Research, 1987, 6, 345-361.	1.1	10
77	Structure determination of VEGF-E by sulfur SAD. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 1430-1434.	2.5	9
78	Domains in Middle-T Antigen That Cooperate in Polyomavirus-Mediated Oncogenic Transformation. Virology, 1995, 208, 26-37.	1.1	8
79	The reception and the party after: how vascular endothelial growth factor receptor 2 explores cytoplasmic space. Swiss Medical Weekly, 2011, 141, w13318.	0.8	8
80	Catalytic activity and transformation potential of v-Src require arginine 385 in the substrate binding pocket. Oncogene, 1995, 10, 199-203.	2.6	8
81	Subcellular object quantification with Squash3C and SquashAnalyst. BioTechniques, 2015, 59, 309-312.	0.8	7
82	Myristylation of pp60c-src is not required for complex formation with polyomavirus middle-T antigen. Journal of Virology, 1990, 64, 5163-5166.	1.5	7
83	Activation-independent nuclear translocation of mitogen activated protein kinase ERK1 mediated by thiol-modifying chemicals. FEBS Letters, 1996, 394, 34-38.	1.3	6
84	HIV TAT Basic Peptide Is Not a High-Affinity Ligand for VEGF Receptor 2. Biological Chemistry, 2003, 384, 1435-1441.	1.2	6
85	Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Oncology Reports, 2007, 18, 933.	1.2	5
86	Insulin-Like Growth Factor-1 Stimulates Proliferation of Myeloid FDC-P1 Cells Overexpressing the Human Colony-Stimulating Factor-1 Receptor. Growth Factors, 1992, 7, 315-325.	0.5	4
87	ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling. International Journal of Molecular Sciences, 2018, 19, 1334.	1.8	4
88	The N terminus of hamster polyomavirus middle T antigen carries a determinant for specific activation of p59c-Fyn. Journal of Virology, 1997, 71, 1436-1442.	1.5	4
89	Cell Lines Expressing Recombinant Transmembrane Domain-Activated Receptor Kinases as Tools for Drug Discovery. Journal of Biomolecular Screening, 2014, 19, 1350-1361.	2.6	3
90	Polyomavirus large- and small-T relieve middle-T-induced cell cycle arrest in normal fibroblasts. Journal of General Virology, 1999, 80, 2917-2921.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Production and Biochemical Characterization of Dimeric Recombinant Gremlin-1. International Journal of Molecular Sciences, 2022, 23, 1151.	1.8	3
92	Membrane association of polyomavirus middle-T antigen in an in vitro system. Virus Research, 1995, 35, 169-180.	1.1	1
93	Finding New Partnerships: The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors. , 2014, , 47-75.		0